2009 Fiscal Year Final Research Report
Stratification of multiple myeloma according to PU.1 expression level
| Project/Area Number |
20790677
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
TATETSU Hiro Kumamoto University, 医学部附属病院, 医員 (00433029)
|
|---|
| Research Collaborator |
OKUNO Yutaka 熊本大学, 医学部・附属病院, 助教 (80363539)
HATA Hiroyuki 熊本大学, 医学部・附属病院, 講師 (70271129)
UENO Shikiko 熊本大学, 医学部・附属病院, 医員 (40571047)
|
|---|
| Project Period (FY) |
2008 – 2009
|
| Keywords | 血液腫瘍学 |
|---|
| Research Abstract |
Multiple myeloma is an incurable hematological malignancy that is resistant to several chemotherapeutic agents so that we need to define new biologic parameters and molecular targets. We previously reported that PU.1 and NF-kB are the molecular targets of multiple myeloma patients. Here, we investigated the correlation between survival of 39 myeloma patients and their expression levels of PU.1 and MUM1 (Multiple Myeloma Oncogene 1 or IRF4). Based on PU.1 and IRF4 expression level, we provisionally divided the myeloma patients into four groups (i.e. (1) PU.1 low IRF4 low、(2) PU.1 low IRF4 high、(3) PU.1 high IRF4 high、 (4) PU.1 high IRF4 high). Patients in low PU.1 and high IRF4 expression subset may have a poor prognosis compared with other groups. Exogenous expression of IRF4 could not cancel the growth arrest of KMS12PE expressing PU.1. Additional follow-up studies will be required to define that the expression levels of PU.1 and IRF4 expressions are useful prognostic factors for multiple myeloma patients.
|
